Subscribe
Spotlight on the new ACC/AHA lipid and JNC8 hypertension guidelines, EGFR inhibitors vs chemotherapy for NSCLC, and more.

JAMA Editor’s Summary

Spotlight on the new ACC/AHA lipid and JNC8 hypertension guidelines, EGFR inhibitors vs chemotherapy for NSCLC, and more.

Editor's Audio Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor, the Journal of the American Medical Association, for the April 09, 2014 issue
April 8, 2014
ADVERTISEMENT
Wise-Formerly Transferwise

Spotlight on the new ACC/AHA lipid and JNC8 hypertension guidelines, EGFR inhibitors vs chemotherapy for NSCLC, and more.

Editor’s Audio Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor, the Journal of the American Medical Association, for the April 09, 2014 issue

ADVERTISEMENT
Wise-Formerly Transferwise

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Proudly supported by:

cover
Javier Lozano - Market-Creating Innovation for Diabetes Care an inspiring conversation with Javier Lozano, Founder and CEO of Clínicas del Azúcar, a growing chain of "one-stop shops" for diabetes care in Mexico.